Hoffmann-La Roche: Alzheimer Disease trials
The registry lists 40 Alzheimer Disease studies with Hoffmann-La Roche as lead sponsor. 3 are open to participants now and 18 have results posted.
Phase 1 14Phase 2 13Phase 3 14(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseaseRecruitingNCT07781657Phase 2
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseaseRecruitingNCT07717411Phase 3
- Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesRecruitingNCT07177352Phase 3
- A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)TerminatedNCT05256134Phase 3Results posted
- A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedNCT04592341Phase 2Results posted
- A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese ParticipantsCompletedNCT04394845Phase 1Results posted
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)TerminatedNCT04374253Phase 3Results posted
- A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)TerminatedNCT04339413Phase 3Results posted
- A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy ParticipantsCompletedNCT04023994Phase 1Results posted
- Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseCompletedNCT03977584Phase 2Results posted
- A Study of Semorinemab in Patients With Moderate Alzheimer's DiseaseCompletedNCT03828747Phase 2Results posted
- An Open-Label Crenezumab Study in Participants With Alzheimer's DiseaseTerminatedNCT03491150Phase 3Results posted
- Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedNCT03444870Phase 3Results posted
- Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedNCT03443973Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's DiseaseTerminatedNCT03289143Phase 2Results posted
- A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)TerminatedNCT03114657Phase 3Results posted
- A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).TerminatedNCT02670083Phase 3Results posted
- A Study of Gantenerumab in Participants With Mild Alzheimer DiseaseCompletedNCT02051608Phase 3Results posted
- A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier CohortCompletedNCT01998841Phase 2Results posted
- A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With CrenezumabCompletedNCT01723826Phase 2Results posted
- A Study of Gantenerumab in Participants With Prodromal Alzheimer's DiseaseCompletedNCT01224106Phase 3Results posted
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)Active, not recruitingNCT07234942Phase 1
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseActive, not recruitingNCT07170150Phase 3
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseActive, not recruitingNCT07169578Phase 3
- A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)Active, not recruitingNCT06402838Phase 2
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseaseActive, not recruitingNCT04639050Phase 1/2
- Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's DiseaseCompletedNCT04566003Phase 1
- A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT02820896Phase 1
- Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease ParticipantsCompletedNCT02792179Phase 1
- Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy ParticipantsCompletedNCT02640092Phase 1
- A Study of Crenezumab in Participants With Mild to Moderate Alzheimer DiseaseCompletedNCT02353598Phase 1
- Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) ParticipantsCompletedNCT02187627Phase 1
- A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy VolunteersCompletedNCT01701089Phase 1
- A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyCompletedNCT01677754Phase 2
- A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsCompletedNCT01656525Phase 1
- A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT01397578Phase 2
- A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)CompletedNCT01343966Phase 2
- A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00884507Phase 2
- A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's DiseaseCompletedNCT00736775Phase 1
- A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.CompletedNCT00531804Phase 1